<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674829</url>
  </required_header>
  <id_info>
    <org_study_id>CHA CTP 1101</org_study_id>
    <nct_id>NCT01674829</nct_id>
  </id_info>
  <brief_title>A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)</brief_title>
  <official_title>A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHABiotech CO., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHABiotech CO., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with&#xD;
      advanced dry AMD To evaluate the safety of the surgical procedures when used to implant&#xD;
      MA09-hRPE cells To assess the number of hRPE cells to be transplanted in future studies To&#xD;
      evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of&#xD;
      MA09-hRPE cellular therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of hESC derived RPE cells</measure>
    <time_frame>12 months</time_frame>
    <description>The transplantation of hESC-derived RPE cells MA09-hRPE will be considered safe in the absence of:&#xD;
Any grade 2 (NCI grading system) or greater adverse event related to the cell product&#xD;
Any evidence that the cells are contaminated with an infectious agent&#xD;
Any evidence that the cells show tumorigenic potential</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>exploratory evaluations for potential efficacy endpoints</measure>
    <time_frame>12months</time_frame>
    <description>Secondary endpoints will be evaluated as exploratory evaluations for potential efficacy endpoints.&#xD;
Change in the mean of BCVA&#xD;
Autofluorescense photography&#xD;
Reading speed&#xD;
Evidence of successful engraftment will consist of:&#xD;
Structural evidence (OCT imaging, fluorescein angiography, slitlamp examination with fundus photography) that cells have been implanted in the correct location&#xD;
Electroretinographic evidence (mfERG) showing enhanced activity in the implant location</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Dry Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Biological: MA09-hRPE Cellular therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: MA09-hRPE Cellular therapy&#xD;
Cohort 1 50,000 cells&#xD;
Cohort 2 100,000 cells&#xD;
Cohort 3 150,000 cells&#xD;
Cohort 4 200,000 cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MA09-hRPE</intervention_name>
    <arm_group_label>Biological: MA09-hRPE Cellular therapy</arm_group_label>
    <other_name>Cohort 1- 50,000 MA09-hRPE cells transplanted</other_name>
    <other_name>Cohort 2- 100,000 MA09-hRPE cells transplanted</other_name>
    <other_name>Cohort 3- 150,000 MA09-hRPE cells transplanted</other_name>
    <other_name>Cohort 4- 200,000 MA09-hRPE cells transplanted</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female over 55 years of age. Patient should be in sufficiently good&#xD;
             health to reasonably expect survival for at least four years after treatment&#xD;
&#xD;
          -  Clinical findings consistent with advanced dry AMD with evidence of one or more areas&#xD;
             of &gt;250microns of geographic atrophy (as defined in the Age-Related eye Disease Study&#xD;
             [AREDS] study) involving the central fovea.&#xD;
&#xD;
          -  GA defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, and FA.&#xD;
&#xD;
          -  No evidence of current or prior choroidal neovascularization in the treated eye&#xD;
&#xD;
          -  The visual acuity (BCVA) of the eye to receive the transplant will be no better than&#xD;
             20/400.&#xD;
&#xD;
          -  The visual acuity (BCVA) of the eye that is NOT to receive the transplant will be no&#xD;
             worse than 20/400.&#xD;
&#xD;
          -  Electrophysiological findings consistent with advanced dry AMD.&#xD;
&#xD;
          -  Medically suitable to undergo vitrectomy and subretinal injection.&#xD;
&#xD;
          -  Medically suitable for general anesthesia or waking sedation, if needed.&#xD;
&#xD;
          -  Medically suitable for transplantation of an embryonic stem cell line:&#xD;
&#xD;
        Any laboratory value which falls slightly outside of the normal range will be reviewed by&#xD;
        the Medical Monitor and Investigators to determine its clinical significance. If it is&#xD;
        determined not to be clinically significant, the patient may be enrolled into the study.&#xD;
&#xD;
        Normal serum chemistry complete blood count [CBC], prothrombin time [PT], and activated&#xD;
        partial thromboplastin time [aPTT] Negative urine screen for drugs of abuse. Negative human&#xD;
        immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) serologies.&#xD;
&#xD;
        No history of malignancy&#xD;
&#xD;
        Negative cancer screening within previous 6 months:&#xD;
&#xD;
        complete history &amp; physical examination; dermatological screening exam for malignant&#xD;
        lesions; negative fecal occult blood test &amp; negative colonoscopy within previous 7 years;&#xD;
        negative chest roentgenogram (CXR); normal CBC &amp; manual differential; negative urinalysis&#xD;
        (U/A); normal thyroid exam; if male, normal testicular examination; digital rectal&#xD;
        examination (DRE) and prostate specific antigen (PSA); if female, normal pelvic examination&#xD;
        with Papanicolaou smear; and If female, normal clinical breast exam and, negative&#xD;
        mammogram. If female and of childbearing potential, willing to use two effective forms of&#xD;
        birth control during the study.&#xD;
&#xD;
        If male, willing to use barrier and spermicidal contraception during the study. Willing to&#xD;
        defer all future blood, blood component or tissue donation. Able to understand and willing&#xD;
        to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of active or inactive CNV in the eye to be treated.&#xD;
&#xD;
          -  Presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis,&#xD;
             central serious choroidopathy, diabetic retinopathy or other retinal vascular or&#xD;
             degenerative disease other than ARMD.&#xD;
&#xD;
          -  History of optic neuropathy.&#xD;
&#xD;
          -  Macular atrophy due to causes other than AMD.&#xD;
&#xD;
          -  Presence of glaucomatous optic neuropathy in the study eye, uncontrolled IOP, or use&#xD;
             of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist,&#xD;
             prostaglandins, anhydrous carbonic inhibitors)&#xD;
&#xD;
          -  Cataract of sufficient severity likely to necessitate surgical extraction within 1&#xD;
             year.&#xD;
&#xD;
          -  History of retinal detachment repair in the study eye.&#xD;
&#xD;
          -  Axial myopia of greater than -8 diopters&#xD;
&#xD;
          -  Axial length greater than 28 mm.&#xD;
&#xD;
          -  History of myocardial infarction in previous 12 months.&#xD;
&#xD;
          -  History of diabetes mellitus.&#xD;
&#xD;
          -  History of cognitive impairments or dementia which may impact the patients ability&#xD;
             participate in the informed consent process and to appropriately complete evaluations.&#xD;
&#xD;
          -  Any immunodeficiency.&#xD;
&#xD;
          -  Any current immunosuppressive therapy other than intermittent or low dose&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Alanine transaminase/aspartate aminotransferase (ALT/AST) &gt;1.5 times the upper limit&#xD;
             of normal or any known liver disease.&#xD;
&#xD;
          -  Renal insufficiency, as defined by creatine level &gt;1.3 mg/dL.&#xD;
&#xD;
          -  A hemoglobin concentration of less than 10 gm/dL, a platelet count of less than&#xD;
             100k/mm3 or an absolute neutrophil count of less than 1000/mm3 at study entry.&#xD;
&#xD;
          -  Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.&#xD;
&#xD;
          -  Current participation in any other clinical trial.&#xD;
&#xD;
          -  Participation within previous 6 months in any clinical trial of a drug by ocular or&#xD;
             systemic administration.&#xD;
&#xD;
          -  Any other sight-threatening ocular disease.&#xD;
&#xD;
          -  Any history of retinal vascular disease (compromised blood-retinal barrier. Glaucoma.&#xD;
&#xD;
          -  Uveitis or other intraocular inflammatory disease.&#xD;
&#xD;
          -  Significant lens opacities or other media opacity.&#xD;
&#xD;
          -  Ocular lens removal within previous 3 months.&#xD;
&#xD;
          -  Ocular surgery in the study eye in the previous 3 months&#xD;
&#xD;
          -  If female, pregnancy or lactation.&#xD;
&#xD;
          -  Any other medical condition, which, in the Investigator's judgment, will interfere&#xD;
             with the patient's ability to comply with the protocol, compromises patient safety, or&#xD;
             interferes with the interpretation of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonkyung Song, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Bundang Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712,</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

